Vaccine report concluding that QS-21 containing formulations of HBsAg induced high quality and persistent humoral and cellular immune responses that persisted at least 4 years after first vaccination in healthy adults.
Vaccine Adjuvant Systems containing monophosphoryl lipid A andQS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination